Bulacan reaches target herd immunity against COVID-19 | Inquirer ºÚÁÏÉç

ºÚÁÏÉç

Bulacan reaches target herd immunity against COVID-19

By: - Correspondent /
/ 03:43 PM April 22, 2022

Gun-toting man nabbed after threatening neighbor over debt in BulacanCITY OF MALOLOS––The province of Bulacan has reached its target herd immunity against COVID-19 after vaccinating more than 2.2 million of its 3.7 million residents, authorities said Friday, April 22.

As of April 17, at least 5.2 million COVID-19 vaccine doses have been administered in the province, with 2,281,195 residents vaccinated fully while 2,418,385 inoculated with the first dose.

Dra. Hjordis Marushka Celis, Bulacan COVID-19 Task Force vice-chair, said 541,091 residents had received booster shots.

Article continues after this advertisement

As of Friday, Bulacan’s active COVID-19 cases dropped to 62.

FEATURED STORIES

Since the pandemic struck in 2020, the province has registered
109,375 COVID-19 cases, with 107,636 recoveries and 1,677 deaths.

The province is on Alert Level 1, the least restrictive in the five-tier alert system in the country. INQ

Article continues after this advertisement

lzb

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the and acknowledge that I have read the .

For more news about the novel coronavirus click
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this

TAGS: Bulacan, COVID-19

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the and acknowledge that I have read the .

© Copyright 1997-2024 ºÚÁÏÉç | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies.